As at 31st October 2022, the number of ordinary shares in issue was 74,142,147.
As at 31st October 2022, the Company has been notified of the following interests in 3% or more of the issued ordinary share capital of the Company.
|No of ordinary shares||%|
|Balderton Capital III,LP||6,813,196||9.19|
|Blind Trust (Richard Sharp)||4,891,444||6.60|
|BNP Paribas Arbitrage||3,850,408||5.19|
|Chelverton Asset Management||4,000,000||5.40|
|Dr Adam M Hill||3,689,734||4.81|
|Genostics Company Ltd||3,335,659||4.50|
|Mr Timothy Brian Bunting||4,856,717||6.55|
|Hargreaves Lansdown Asset Management||2,717,717||3.67|
|HSBC Holdings Plc||2,539,848||3.43|
- Mr Bunting is a partner of Balderton Capital (UK) LLP the investment adviser to Balderton Capital Partners III, LP.
- Dr Hill is Chief Executive Officer of Oncimmune and holds 73,872 shares and 3,689,734 options to acquire shares in the Company. The percentage holding has been calculated based on the current number of ordinary shares in issue.
|No of shares||No of share options||No of warrants|
|Dr Adam M Hill||73,872||3,689,734||–|
Shares not in public hands
In accordance with the definition in the AIM Rules for Companies and insofar as it is aware, as at 31st October 2022, 24,21% of the Company’s AIM securities was not in public hands.
Restrictions on transfer of Aim Securities
There are no restrictions on the transfer of securities.
UK City Code on takeovers and mergers
Oncimmune Holdings Plc is subject to the UK City Code on Takeovers and Mergers.
Details of other exchanges or trading platforms
Other than AIM, the Company’s shares are not admitted to or traded on any other exchanges or trading platforms.
Page last updated: 19th December 2022